Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Condray R, Dougherty GG Jr, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK.

Int J Neuropsychopharmacol. 2011 Jul;14(6):756-67. doi: 10.1017/S1461145710001689. Epub 2011 Jan 28.

2.

Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.

Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S, Steinbusch HW, Leonard BE, Kim YK.

Brain Behav Immun. 2011 Nov;25(8):1576-81. doi: 10.1016/j.bbi.2011.05.005. Epub 2011 May 17.

PMID:
21620952
3.

Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R.

Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.

4.

Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration.

Lee M, Jayathilake K, Dai J, Meltzer HY.

Psychiatry Res. 2011 Feb 28;185(3):328-33. doi: 10.1016/j.psychres.2010.07.013. Epub 2010 Aug 10.

PMID:
20699195
5.

Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.

Schwieler L, Samuelsson M, Frye MA, Bhat M, Schuppe-Koistinen I, Jungholm O, Johansson AG, Landén M, Sellgren CM, Erhardt S.

J Neuroinflammation. 2016 Feb 29;13(1):51. doi: 10.1186/s12974-016-0517-7.

6.

Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.

Szymona K, Zdzisińska B, Karakuła-Juchnowicz H, Kocki T, Kandefer-Szerszeń M, Flis M, Rosa W, Urbańska EM.

Neurotox Res. 2017 Jul;32(1):17-26. doi: 10.1007/s12640-017-9714-0. Epub 2017 Mar 8.

PMID:
28275903
7.

Serum kynurenic acid is reduced in affective psychosis.

Wurfel BE, Drevets WC, Bliss SA, McMillin JR, Suzuki H, Ford BN, Morris HM, Teague TK, Dantzer R, Savitz JB.

Transl Psychiatry. 2017 May 2;7(5):e1115. doi: 10.1038/tp.2017.88.

8.

The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.

Guloksuz S, Arts B, Walter S, Drukker M, Rodriguez L, Myint AM, Schwarz MJ, Ponds R, van Os J, Kenis G, Rutten BP.

Brain Behav Immun. 2015 Aug;48:48-52. doi: 10.1016/j.bbi.2015.02.029. Epub 2015 Mar 9.

PMID:
25765557
9.

Does escitalopram reduce neurotoxicity in major depression?

Halaris A, Myint AM, Savant V, Meresh E, Lim E, Guillemin G, Hoppensteadt D, Fareed J, Sinacore J.

J Psychiatr Res. 2015 Jul-Aug;66-67:118-26. doi: 10.1016/j.jpsychires.2015.04.026. Epub 2015 May 12.

PMID:
26009299
10.

Associations between purine metabolites and clinical symptoms in schizophrenia.

Yao JK, Condray R, Dougherty GG Jr, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Reddy RD.

PLoS One. 2012;7(8):e42165. doi: 10.1371/journal.pone.0042165. Epub 2012 Aug 14.

11.

[The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].

Flis M, Szymona K, Morylowska-Topolska J, Urbańska A, Krukow P, Kandefer-Szerszeń M, Zdzisińska B, Urbańska EM, Karakuła-Juchnowicz H.

Pol Merkur Lekarski. 2016 Sep 29;41(243):160-164. Review. Polish.

PMID:
27755520
12.

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS.

Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15. Erratum in: Am J Psychiatry. 2009 Jun;166(6):731.

PMID:
19369319
13.

Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression.

Veen C, Myint AM, Burgerhout KM, Schwarz MJ, Schütze G, Kushner SA, Hoogendijk WJ, Drexhage HA, Bergink V.

J Affect Disord. 2016 Jan 1;189:298-305. doi: 10.1016/j.jad.2015.09.064. Epub 2015 Oct 22.

PMID:
26454336
14.

[Minor neurological and physical anomalies in patients with first-episode psychosis].

Mhalla A, Boussaïd N, Gassab L, Gaha L, Mechri A.

Encephale. 2013 Jun;39(3):149-54. doi: 10.1016/j.encep.2012.06.030. Epub 2012 Oct 12. French.

PMID:
23095597
15.

Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.

Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS, Bodurka J, Teague TK, Dantzer R.

Neuropsychopharmacology. 2015 Jan;40(2):463-71. doi: 10.1038/npp.2014.194. Epub 2014 Jul 30.

16.

Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients.

Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B.

Neuropsychobiology. 2009;59(2):123-9. doi: 10.1159/000213565. Epub 2009 Apr 22.

PMID:
19390223
17.

Kynurenine and its metabolites in Alzheimer's disease patients.

Gulaj E, Pawlak K, Bien B, Pawlak D.

Adv Med Sci. 2010;55(2):204-11. doi: 10.2478/v10039-010-0023-6.

PMID:
20639188
18.

Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry.

de Jong WH, Smit R, Bakker SJ, de Vries EG, Kema IP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 1;877(7):603-9. doi: 10.1016/j.jchromb.2009.01.015. Epub 2009 Jan 21.

PMID:
19196554
19.

Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.

Dahl J, Andreassen OA, Verkerk R, Malt UF, Sandvik L, Brundin L, Ormstad H.

Psychoneuroendocrinology. 2015 Jun;56:12-22. doi: 10.1016/j.psyneuen.2015.02.011. Epub 2015 Feb 25.

PMID:
25770856
20.

Kynurenine pathway in psychosis: evidence of increased tryptophan degradation.

Barry S, Clarke G, Scully P, Dinan TG.

J Psychopharmacol. 2009 May;23(3):287-94. doi: 10.1177/0269881108089583. Epub 2008 Jun 18.

PMID:
18562404

Supplemental Content

Support Center